FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

BACKGROUND. With the exception of trastuzumab, therapies directed at receptor tyrosine kinases (RTKs) in gastroesophageal adenocarcinomas (GEA) have had limited success. Recurrent fibroblast growth factor receptor 2 (FGFR2) alterations exist in GEA; however, little is known about the genomic landsca...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Klempner, Samuel J., Madison, Russell, Pujara, Vivek, Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B., Kim, Seung Tae, Maron, Steven B., Dayyani, Farshid, Catenacci, Daniel V.T., Lee, Jeeyun, Chao, Joseph
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Inc. 2019
Предметы:
Gastrointestinal Cancer
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853122/
https://ncbi.nlm.nih.gov/pubmed/31249137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0121
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы